- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00787358
A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)
A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women With Intertrochanteric Fracture of the Hip
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- J. Edward Puzas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects are required to meet all of the following criteria for inclusion in the study:
- Signed Institutional Review Board (IRB)/Research Ethics Board (REB)-approved informed consent form (ICF).
- Sustained an unstable low energy intertrochanteric (Evans Type II or higher) hip fracture within 7 days prior to planned surgery date. Low energy is defined as a fracture that occurs spontaneously or from a fall from a stationary height of ≤ 1 meter (3 feet) or missing one to three steps.
- Women ≥ 55 years of age and men ≥ 30 years of age of any race. If female, subjects must be post-menopausal for at least 5 years and weigh ≥ 110 lbs or 50 kg.
- Subjects who are expected to undergo or have recently undergone (within two weeks) open or closed repair of the fracture requiring a CHS.
- By history, the subject was at least household ambulatory prior to hip fracture.
- Serum calcium level within the normal range when corrected for albumin. Corrected calcium (mg/dL) = Serum Ca (mg/dL) + 0.8 x (4.0 - albumin [g/dL])
- Able and willing to comply with all protocol procedures.
- Cognitive, visual, auditory and physical abilities adequate to undertake assessments.
- Availability of a care partner to administer injections or demonstrated ability to self-administer injections. Subjects planning to self-administer study drug will need to show that they will be capable of accurately self-injecting study drug in rotating quadrants of the abdomen, in the opinion of the Investigator.
- Clinically acceptable medical history and physical examination, according to the judgment of the Investigator.
Laboratory results within normal ranges or, if abnormal, considered by the Investigator as not clinically significant for the well-being of the subject or for the purpose of the study.
The following additional criteria are required for randomization and dosing with ZT-031 or placebo to occur:
- The most recent value for 25-hydroxy Vitamin D (25OHD) must be at or above the lower limit of normal (LLN) for the laboratory reference range of the testing method used for determination of 25OHD. NOTE: Randomization should be delayed until it is known that 25OHD is ≥ LLN.
- The most recent value for intact PTH must be ≤ ULN for the laboratory reference range.
- Randomization and dosing must occur within 2 weeks post-op. Exclusion Criteria
Subjects who meet any of the following conditions are excluded from this clinical study:
- Previous fracture(s) or bone or joint surgery in the currently fractured site
- Intertrochanteric fracture with reverse obliquity
- Pathologic fracture: A fracture occurring at a site of metabolic bone disease (other than osteoporosis) or a benign or malignant tumor
- Presence of a concurrent disease known to affect bone metabolism other than post-menopausal osteoporosis, including but not limited to hyperparathyroidism, hyperthyroidism, osteogenesis imperfecta, abnormalities of serum calcium, Paget's disease, or osteomalacia
- History of rheumatoid arthritis
- Any significant neurologic disease including but not limited to any dementing illness or other neurodegenerative disease, cerebrovascular disease, epilepsy or undiagnosed syncope
Unstable or clinically significant cardiovascular disease resulting in:
- Hemodynamic instability manifested as hypotension unresponsive to intravenous fluids
- Uncontrolled hypertension requiring administration of parenteral therapy.
Renal disease, defined by:
- Creatinine level of >2.0 mg/dL
- Urolithiasis or nephrolithiasis in the last 2 years
- Hepatic disease or insufficiency, defined by liver function tests (ALT, AST or GGT) > 3 times the ULN or bilirubin > 34 mmol/L or 2.0 mg/dL
- Currently receiving treatment for cancer
- History of external beam radiation to the skeleton or a radiation therapy implant device
- Presence of substance abuse, including alcohol, within 1 year of Screening
- Current or previous use of any PTH compound, including ZT-031
- Use of any investigational compound within 4 weeks of Screening, or within 5 half-lives of compound, whichever is longer
- Use of any bone substitutes, osteobiologics or any fracture healing drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
80 ul daily subcutaneous injection of vehicle only
|
Active Comparator: ZT-031
|
80 ul subcutaneous injection per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compression hip screw (CHS) migration: the difference in the tip apex distance (TAD) post-operatively to that at Visit 7/Week 16
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Screw barrel impaction distance
Time Frame: 16 weeks
|
16 weeks
|
Screw cut-out and/or other hardware failure
Time Frame: 16 weeks
|
16 weeks
|
Incidence of fracture non-union
Time Frame: 16 weeks
|
16 weeks
|
Need for surgical revision with or without hardware removal
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OC-018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hip Fracture
-
University Health Network, TorontoNot yet recruitingSurgery | Hip-fracture
-
Lund UniversityMalmo Municipality, SwedenRecruiting
-
Hvidovre University HospitalCompleted
-
Michal Roll PhD,MBATel-Aviv Sourasky Medical CenterUnknown
-
The University of Hong KongRecruiting
-
Mayo ClinicCompletedPertrochanteric Hip FractureUnited States
-
Eurofarma Laboratorios S.A.TerminatedHip Fracture SurgeryBrazil
-
National Institute of Arthritis and Musculoskeletal...Completed
-
Guy's and St Thomas' NHS Foundation TrustCompletedHip Fractures | Fracture of Hip | Fractured HipUnited Kingdom
Clinical Trials on ZT-031
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Hangzhou Jiayin Biotech LtdRecruiting
-
Eleven BiotherapeuticsWithdrawn
-
Basking Biosciences, Inc.CompletedHealthy Volunteers | Pharmacokinetics | PharmacodynamicsAustralia
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Terminated
-
Antengene Biologics LimitedRecruitingAdvanced Solid Tumors | B-cell Non-Hodgkin LymphomasUnited States
-
Exegenesis BioRecruitingNeovascular (Wet) Age-related Macular Degeneration (nAMD)United States
-
Acceleron Pharma Inc. (a wholly owned subsidiary...Completed
-
Basking Biosciences, Inc.Not yet recruitingAcute Ischemic Stroke
-
Huashan HospitalRecruitingProstate Specific Membrane Antigen Positive Metastatic Prostate CancerChina